The Committee for Medicinal Products for Human Use (CHMP) decided that, in combination with other anticancer medicines, Avastin’ s benefits are greater than its risks for the treatment of metastatic 2/ 3 cancer of colon or rectum, and the first-line treatment of metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer with other than predominantly squamous cell histology, and advanced and/ or metastatic renal cell cancer.